Penpulimab

Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities[1].

Product Specifications

CAS Number

[2350298-92-7]

Product Name Alternative

AK-105

UNSPSC

12352203

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/penpulimab.html

Purity

98.80

Solubility

H2O

Smiles

[Penpulimab]

Molecular Weight

(145.14 kDa)

References & Citations

[1]Huang Z, et al. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. Front Immunol. 2022 Jun 27;13:924542.|[2]Yunlong Shan, et al. Anlotinib enhanced penpulimab efficacy through remodeling of tumor vascular architecture and immune microenvironment in hPD-L1/hPD-1 humanized mouse model. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 2581-2581.